ArticleHuman vaccines & immunotherapeutics2018

Safety and immunogenicity of an upper-range release titer measles-mumps-rubella vaccine in children vaccinated at 12 to 15 months of age: a phase III, randomized study.

MMR-162 Study GroupPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.